Roger Bakale, Ph.D.

Dr. Bakale joined Kura in April 2020 with more than 35 years of Pharmaceutical R&D experience. Previously, he was Vice President of CMC-Product Development & Manufacturing Bristol-Myers Squibb (formerly Celgene). Before the Bristol-Myers Squibb and Celgene merger, he was Vice President CMC & Clinical Supply Chain at Celgene (Receptos Inc.). In his career, Dr. Bakale has also served as the Sr. Director and Head of Chemical Process R&D in the Discovery & Product Development division of Teva Global R&D, as well as Senior Managerial and Research and Development positions at Sepracor Inc. (Sunovion) and in scientific leadership positions at Bristol- Myers Squibb and Warner Lambert Parke Davis. He has been responsible for leading the CMC teams associated with the successful drug development and technology transfers of commercial API and drug product launches for seven new patient therapies including: Zeposia™, Treanda™, Synribo™, Xopenex HCl™, Xopenex HFA™, Lunesta™, Bravana™, Soltara™ and also significantly contributing to the technical approval packages of Paclitaxel™ and Fosinopril Sodium^®. Dr. Bakale received his BSc in Chemistry and BSc in Biology at Hope College and his Ph.D. in Synthetic Organic Chemistry under the direction of Professor Carl R. Johnson at Wayne State University.